lewisi in both splenectomised and Cy-treated rats, while inhibition of its production by mercaptopurine
led to the development of a moderate disease.
Identifying patients having high risk of developing toxicity with mercaptopurine is important as toxicity gives undue morbidity and mortality (7,8,22).
Mercaptopurine pharmacogenetics: monogenie inheritance of erythrocyte thiopurine methyltransferase activity.
Jude research that showed variations in another gene, TPMT, were also associated with an increased risk of mercaptopurine
Molecular diagnosis of thiopurine S-kmethyltransferase deficiency: genetic basis for azathioprine and mercaptopurine
leukemia is related to RBC methotrexate and mercaptopurine
metabolites during maintenance chemotherapy.
Kinetics of mercaptopurine
and thioguanine nucleotides in renal transplant recipients during azathioprine treatment.
(MP),  the analog of hypoxanthine, is an antileukemic agent widely used to treat acute lymphoblastic leukemia (ALL) (1).
TPMT is an enzyme known to be involved specifically in the metabolism of mercaptopurine
, which is commonly used for childhood acute lymphoblastic leukemia, and the immunosuppressant azathioprine (Imuran).
metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphoblastic leukemia.
pharmacogenetics: monogenetic inheritance of erythrocyte thiopurine methyltransferase activity.
Patients with chronically active disease who appear to be "steroid dependent" may benefit from treatment with azathioprine or mercaptopurine
in an effort to eliminate the use of corticosteroids.